{"id":7612,"date":"2025-12-22T15:23:52","date_gmt":"2025-12-22T06:23:52","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4506\/"},"modified":"2026-08-23T12:11:53","modified_gmt":"2026-08-23T03:11:53","slug":"company-4506","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4506\/","title":{"rendered":"SUMITOMO PHARMA CO LTD"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4506","DATE":"2025-12-22","longName":"Sumitomo Pharma Co., Ltd.","company_name_ja":"","fullTimeEmployees":3832,"address":"","phone":"","website":"https:\/\/www.sumitomo-pharma.com","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":2288.5,"financialCurrency":"","marketCap":909197,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":453294000000,"OperatingIncome":105053000000,"operatingMargins":23.18,"NetIncome":106865000000,"profitMargins":23.579999999999998,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":36.539999999999999,"recommendationMean":2.4285700000000001,"recommendationKey":"buy","targetMeanPrice":2085.7143999999998,"numberOfAnalystOpinions":6,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T04:56:49.628914\", \"ticker\": \"4506\", \"ticker_full\": \"4506.T\", \"company_name\": \"SUMITOMO PHARMA CO LTD\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 2, \"buy\": 1, \"hold\": 2, \"sell\": 1, \"strong_sell\": 0, \"total_analysts\": 6, \"recommendation_key\": \"buy\", \"recommendation_mean\": 2.42857}, \"target_prices\": {\"has_data\": true, \"current\": 1248.0, \"high\": 2600.0, \"low\": 1500.0, \"mean\": 2085.7144, \"median\": 2200.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": null, \"future_count\": 0, \"past_earnings\": [{\"date\": \"2026-07-30\", \"eps_estimate\": 19.13, \"eps_actual\": 39.02, \"surprise_pct\": 103.97}, {\"date\": \"2026-05-13\", \"eps_estimate\": -15.24, \"eps_actual\": -2.04, \"surprise_pct\": 86.61}, {\"date\": \"2026-01-30\", \"eps_estimate\": -0.87, \"eps_actual\": 22.19, \"surprise_pct\": 2650.57}, {\"date\": \"2025-10-30\", \"eps_estimate\": 18.07, \"eps_actual\": 220.63, \"surprise_pct\": 1120.81}, {\"date\": \"2025-07-31\", \"eps_estimate\": 20.59, \"eps_actual\": 28.21, \"surprise_pct\": 37.01}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 48.83, \"institution_pct\": 20.37, \"major_holders\": [{\"label\": \"\", \"value\": 48.83}, {\"label\": \"\", \"value\": 20.37}, {\"label\": \"\", \"value\": 39.82}, {\"label\": \"\", \"value\": 136.0}], \"institutional_holders\": [{\"holder\": \"Legato Capital Management LLC\", \"shares\": 41081, \"date_reported\": \"2022-09-30\", \"pct_held\": 0.01, \"pct_change\": 52.5, \"value\": 51269088}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 2730207, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.61, \"pct_change\": 10.61, \"value\": 3407298336}, {\"holder\": \"iShares Trust-iShares Core MSCI EAFE ETF\", \"shares\": 1711400, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.38, \"pct_change\": 0.0, \"value\": 2135827200}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 1642701, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.37, \"pct_change\": 2.37, \"value\": 2050090848}, {\"holder\": \"T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Discovery Fd.\", \"shares\": 1524900, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.34, \"pct_change\": 1.0, \"value\": 1903075200}, {\"holder\": \"Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.\", \"shares\": 1438800, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.32, \"pct_change\": -27.37, \"value\": 1795622400}, {\"holder\": \"iShares Trust-iShares MSCI EAFE Small-Cap ETF\", \"shares\": 955800, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.21, \"pct_change\": -0.25, \"value\": 1192838400}, {\"holder\": \"iShares Trust-iShares International Equity Factor ETF\", \"shares\": 636000, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.14, \"pct_change\": 44.25, \"value\": 793728000}, {\"holder\": \"Mercer Funds-Mercer Non-US Core Equity Fund\", \"shares\": 430400, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.1, \"pct_change\": 12.35, \"value\": 537139200}, {\"holder\": \"VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Index Fd.\", \"shares\": 440150, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.1, \"pct_change\": 18.15, \"value\": 549307200}, {\"holder\": \"SCHWAB STRATEGIC TRUST-Schwab International Equity ETF\", \"shares\": 443169, \"date_reported\": \"2026-05-31\", \"pct_held\": 0.1, \"pct_change\": 28.3, \"value\": 553074912}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":7,"get_dividend_history_year2":28,"get_dividend_history_year3":28,"get_dividend_history_year4":28,"get_dividend_history_year5":35,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T03:05:22.859542\", \"ticker\": \"4506\", \"ticker_full\": \"4506.T\", \"company_name\": \"SUMITOMO PHARMA CO LTD\", \"company_info\": {\"name_en\": \"SUMITOMO PHARMA CO LTD\", \"long_name\": \"Sumitomo Pharma Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.sumitomo-pharma.com\", \"employees\": null, \"country\": \"Japan\", \"city\": \"Osaka\", \"address\": \"2-6-8 Doshomachi\", \"description\": \"Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 1391.5, \"deviation\": 1.44, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 1315.04, \"deviation\": 7.34, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 1442.6, \"deviation\": -2.16, \"trend\": \"down\"}, \"ma_200\": {\"ma_value\": 1945.16, \"deviation\": -27.44, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 453294000000.0, \"revenue_fmt\": \"\u00a54533\u5104\", \"gross_profit\": 256893000000.0, \"gross_profit_fmt\": \"\u00a52569\u5104\", \"operating_income\": 105053000000.0, \"operating_income_fmt\": \"\u00a51051\u5104\", \"ebit\": 110536000000.0, \"ebit_fmt\": \"\u00a51105\u5104\", \"net_income\": 106865000000.0, \"net_income_fmt\": \"\u00a51069\u5104\", \"eps\": 0, \"operating_margin\": 23.18, \"total_assets\": 804571000000.0, \"total_assets_fmt\": \"\u00a58046\u5104\", \"total_equity\": 292467000000.0, \"total_equity_fmt\": \"\u00a52925\u5104\", \"total_debt\": 217186000000.0, \"total_debt_fmt\": \"\u00a52172\u5104\", \"total_cash\": 44310000000.0, \"total_cash_fmt\": \"\u00a5443\u5104\", \"equity_ratio\": 36.35, \"de_ratio\": 0.74, \"current_ratio\": 1.03, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 23.58, \"roe\": 36.54, \"roa\": 13.28}, {\"year\": 2025, \"revenue\": 398832000000.0, \"revenue_fmt\": \"\u00a53988\u5104\", \"gross_profit\": 245395000000.0, \"gross_profit_fmt\": \"\u00a52454\u5104\", \"operating_income\": 29709000000.0, \"operating_income_fmt\": \"\u00a5297\u5104\", \"ebit\": 31111000000.0, \"ebit_fmt\": \"\u00a5311\u5104\", \"net_income\": 23634000000.0, \"net_income_fmt\": \"\u00a5236\u5104\", \"eps\": 59.49, \"operating_margin\": 7.45, \"total_assets\": 742604000000.0, \"total_assets_fmt\": \"\u00a57426\u5104\", \"total_equity\": 169479000000.0, \"total_equity_fmt\": \"\u00a51695\u5104\", \"total_debt\": 305422000000.0, \"total_debt_fmt\": \"\u00a53054\u5104\", \"total_cash\": 23116000000.0, \"total_cash_fmt\": \"\u00a5231\u5104\", \"equity_ratio\": 22.82, \"de_ratio\": 1.8, \"current_ratio\": 1.05, \"operating_cf\": 16500000000.0, \"operating_cf_fmt\": \"\u00a5165\u5104\", \"investing_cf\": 99754000000.0, \"investing_cf_fmt\": \"\u00a5998\u5104\", \"financing_cf\": -108836000000.0, \"financing_cf_fmt\": \"-\u00a51088\u5104\", \"free_cf\": 3470000000.0, \"free_cf_fmt\": \"\u00a535\u5104\", \"net_margin\": 5.93, \"roe\": 13.95, \"roa\": 3.18}, {\"year\": 2024, \"revenue\": 314558000000.0, \"revenue_fmt\": \"\u00a53146\u5104\", \"gross_profit\": 187981000000.0, \"gross_profit_fmt\": \"\u00a51880\u5104\", \"operating_income\": -354836000000.0, \"operating_income_fmt\": \"-\u00a53548\u5104\", \"ebit\": -318837000000.0, \"ebit_fmt\": \"-\u00a53188\u5104\", \"net_income\": -314969000000.0, \"net_income_fmt\": \"-\u00a53150\u5104\", \"eps\": -792.79, \"operating_margin\": -112.8, \"total_assets\": 907506000000.0, \"total_assets_fmt\": \"\u00a59075\u5104\", \"total_equity\": 156063000000.0, \"total_equity_fmt\": \"\u00a51561\u5104\", \"total_debt\": 418884000000.0, \"total_debt_fmt\": \"\u00a54189\u5104\", \"total_cash\": 29047000000.0, \"total_cash_fmt\": \"\u00a5290\u5104\", \"equity_ratio\": 17.2, \"de_ratio\": 2.68, \"current_ratio\": 0.52, \"operating_cf\": -241893000000.0, \"operating_cf_fmt\": \"-\u00a52419\u5104\", \"investing_cf\": 33036000000.0, \"investing_cf_fmt\": \"\u00a5330\u5104\", \"financing_cf\": 77851000000.0, \"financing_cf_fmt\": \"\u00a5779\u5104\", \"free_cf\": -257623000000.0, \"free_cf_fmt\": \"-\u00a52576\u5104\", \"net_margin\": -100.13, \"roe\": -201.82, \"roa\": -34.71}, {\"year\": 2023, \"revenue\": 555544000000.0, \"revenue_fmt\": \"\u00a55555\u5104\", \"gross_profit\": 376625000000.0, \"gross_profit_fmt\": \"\u00a53766\u5104\", \"operating_income\": -76979000000.0, \"operating_income_fmt\": \"-\u00a5770\u5104\", \"ebit\": -44761000000.0, \"ebit_fmt\": \"-\u00a5448\u5104\", \"net_income\": -74512000000.0, \"net_income_fmt\": \"-\u00a5745\u5104\", \"eps\": -187.55, \"operating_margin\": -13.86, \"total_assets\": 1134742000000.0, \"total_assets_fmt\": \"\u00a51.1T\", \"total_equity\": 406749000000.0, \"total_equity_fmt\": \"\u00a54067\u5104\", \"total_debt\": 334716000000.0, \"total_debt_fmt\": \"\u00a53347\u5104\", \"total_cash\": 143478000000.0, \"total_cash_fmt\": \"\u00a51435\u5104\", \"equity_ratio\": 35.85, \"de_ratio\": 0.82, \"current_ratio\": 1.02, \"operating_cf\": 11937000000.0, \"operating_cf_fmt\": \"\u00a5119\u5104\", \"investing_cf\": 52419000000.0, \"investing_cf_fmt\": \"\u00a5524\u5104\", \"financing_cf\": -146817000000.0, \"financing_cf_fmt\": \"-\u00a51468\u5104\", \"free_cf\": -805000000.0, \"free_cf_fmt\": \"-\u00a58\u5104\", \"net_margin\": -13.41, \"roe\": -18.32, \"roa\": -6.57}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 141.99, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 31239000000.0, \"operating_cf_fmt\": \"\u00a5312\u5104\", \"investing_cf\": -18278000000.0, \"investing_cf_fmt\": \"-\u00a5183\u5104\", \"financing_cf\": -21426000000.0, \"financing_cf_fmt\": \"-\u00a5214\u5104\", \"free_cf\": 17745000000.0, \"free_cf_fmt\": \"\u00a5177\u5104\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2019, \"amount\": 35.0}, {\"year\": 2020, \"amount\": 28.0}, {\"year\": 2021, \"amount\": 28.0}, {\"year\": 2022, \"amount\": 28.0}, {\"year\": 2023, \"amount\": 7.0}], \"latest\": 7.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-7612","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SUMITOMO PHARMA CO LTD - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4506\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4506\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4506\/\",\"name\":\"SUMITOMO PHARMA CO LTD - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2025-12-22T06:23:52+00:00\",\"dateModified\":\"2026-08-23T03:11:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4506\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4506\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4506\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SUMITOMO PHARMA CO LTD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SUMITOMO PHARMA CO LTD - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4506\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4506\/","url":"https:\/\/japanir.jp\/en\/company\/company-4506\/","name":"SUMITOMO PHARMA CO LTD - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2025-12-22T06:23:52+00:00","dateModified":"2026-08-23T03:11:53+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4506\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4506\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4506\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"SUMITOMO PHARMA CO LTD"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/7612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=7612"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=7612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}